Pharmaceuticals & Therapeutics

As Stoke prepares for a key investor conference, its lead drug zorevunersen nears a pivotal Phase 3 readout, promising a new era for patients and the RNA platform.

A landmark deal for a traditional medicine ingredient is about more than wellness. It’s a calculated play to reshape Macau's future beyond the casino floor.

MedMark Treatment Centers is expanding buprenorphine access in nine states, reflecting a national shift toward patient-centric opioid recovery models.

With new data on its recently approved therapy TREGZI™, Orca Bio aims to shift the goal of cancer transplants from mere survival to a life free of complications.

With Hepatitis C royalties declining, Enanta Pharmaceuticals faces investors this month to sell its vision: a future built on novel RSV and immunology drugs.

An estimated 13 million Americans live with Dupuytren's contracture, a progressive hand condition. A new campaign using mixed reality aims to change that.

XYRA's new trial uses data from wearables to personalize doses of Budiodarone, a safer alternative to today's standard AF drugs. Is this the future?

After a strategic reset, Australian biopharma Immuron reports record sales and a stronger cash position, pivoting to partner its high-value drug candidates.

GRI Bio showcases its promising IPF drug, GRI-0621, in a new webcast, aiming to capture investor and scientific attention before a key industry congress.

Cardurion is set to reveal pivotal Phase 2 data for Tovinontrine, a first-in-class drug aiming to help millions suffering from chronic heart failure.

As Ottawa champions a 'Buy Canadian' movement, local retailers argue federal nicotine pouch rules are crippling their businesses and fueling a black market.

Xeris Biopharma's XP-8121 aims to solve a key problem in hypothyroidism. Can this weekly injection capture a multi-billion dollar market from daily pills?

A German biotech's novel drug just won a key FDA designation, a strategic move that could redefine the limits of liver surgery and cancer treatment.

The strategic acquisition combines engineered probiotics with CRISPR-based technology, creating a powerful new toolkit to revolutionize livestock health.

A 2024 law meant to protect youth from nicotine pouches has instead fueled a massive, unregulated market, leaving consumers and regulators in a bind.

As Mesoblast prepares its year-end webcast, investors weigh a stellar $115M Ryoncil launch against cash burn and the high-stakes progress of its next-gen therapies.

As AN2 Therapeutics bets its future on novel boron-based drugs, the appointment of Dr. Cameron Trenor signals a critical shift from promise to proof.

PTC Therapeutics' Sephience isn't just another drug; it's a potential life-changer for PKU patients, promising to ease the burden of a lifelong restrictive diet.

FDA clearance for Roche's pTau217 blood test isn't just a clinical win; it's a strategic move to dominate a $27B market by making diagnosis simple and scalable.

Takeda's ORZEYFUL, a first-in-class orexin agonist, wins approval in Japan, offering the first treatment for the root cause of Narcolepsy Type 1.